Lahiry Suman, Levi Christopher, Kim Joosup, Cadilhac Dominique A, Searles Andrew
Centre for Clinical Epidemiology and Biostatistics (CCEB), Community Medicine and Clinical Epidemiology, School of Medicine and Public Health (SMPH), Hunter Medical Research Institute (HMRI), University of Newcastle, Callaghan, NSW, Australia.
Sydney Partnership for Health Education Research and Enterprise (SPHERE), Medicine, University of New South Wales, Sydney, NSW, Australia.
Front Public Health. 2018 Mar 5;6:43. doi: 10.3389/fpubh.2018.00043. eCollection 2018.
In regional and rural Australia, patients experiencing ischemic stroke do not have equitable access to an intravenous recombinant tissue plasminogen activator (tPA). Although thrombolysis with tPA is a clinically proven and cost-effective treatment for eligible stroke patients, there are few economic evaluations on pre-hospital triage interventions to improve access to tPA.
To describe the potential cost-effectiveness of the pre-hospital acute stroke triage (PAST) protocol implemented to provide priority transfer of appropriate patients from smaller hospitals to a primary stroke center (PSC) in regional New South Wales, Australia.
The PAST protocol was evaluated using a prospective and historical control design. Using aggregated administrative data, a decision analytic model was used to simulate costs and patient outcomes. During the implementation of the PAST protocol (intervention), patient data were collected prospectively at the PSC. Control patients included two groups (i) patients arriving at the PSC in the 12 months before the implementation of the PAST protocol and, (ii) patients from the geographical catchment area of the smaller regional hospitals that were previously not bypassed during the control period. Control data were collected retrospectively. The primary outcome of the economic evaluation was the additional cost per disability adjusted life years (DALYs) averted in the intervention period compared to the control period.
The intervention was associated with a 17 times greater odds of eligible patients receiving tPA (adjusted odds ratio, 95% CI 9.42-31.2, < 0.05) and the majority of the associated costs were incurred during acute care and rehabilitation. Overall, the intervention was associated with an estimated net avoidance of 93.3 DALYs. The estimated average cost per DALY averted per patient in the intervention group compared to the control group was $10,921.
Based on our simulation modeling, the pre-hospital triage intervention was a potentially cost-effective strategy for improving access to tPA therapy for patients with ischemic stroke in regional Australia.
在澳大利亚的地区和农村地区,缺血性中风患者无法平等地获得静脉注射重组组织型纤溶酶原激活剂(tPA)。尽管tPA溶栓是经临床验证且具有成本效益的适合中风患者的治疗方法,但针对改善tPA可及性的院前分诊干预措施的经济评估却很少。
描述在澳大利亚新南威尔士州地区实施的院前急性中风分诊(PAST)方案的潜在成本效益,该方案旨在将合适的患者从较小医院优先转运至初级中风中心(PSC)。
采用前瞻性和历史性对照设计对PAST方案进行评估。利用汇总的行政数据,使用决策分析模型模拟成本和患者结局。在PAST方案实施期间(干预阶段),在PSC前瞻性收集患者数据。对照患者包括两组:(i)在PAST方案实施前12个月到达PSC的患者,以及(ii)来自较小地区医院地理服务区域且在对照期之前未被绕过的患者。对照数据进行回顾性收集。经济评估的主要结局是与对照期相比,干预期每避免一个伤残调整生命年(DALY)的额外成本。
干预措施使符合条件的患者接受tPA的几率提高了17倍(调整后的优势比,95%置信区间9.42 - 31.2,<0.05),且大部分相关成本发生在急性护理和康复期间。总体而言,该干预措施估计可净避免93.3个DALY。与对照组相比,干预组每位患者每避免一个DALY的估计平均成本为10,921美元。
基于我们的模拟模型,院前分诊干预是改善澳大利亚地区缺血性中风患者tPA治疗可及性的一种潜在具有成本效益的策略。